PRESS RELEASE published on 06/03/2024 at 14:35, 5 months 17 days ago TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) TuHURA and Kintara announce positive results from TuHURA's Phase 1b trial evaluating IFx-2.0 in ICI naïve patients with advanced MCC and cSCC, overcoming resistance to ICI therapy. Data presented at 2024 ASCO Annual Meeting Phase 1b Trial TuHURA Kintara IFx-2.0 Resistance To ICI Therapy
BRIEF published on 04/03/2024 at 13:05, 7 months 17 days ago Kintara Therapeutics et TuHURA Biosciences annoncent un accord de fusion pour faire progresser le pipeline d'oncologie Accord De Fusion Thérapeutique En Oncologie Essais De Phase 3 Résistance À L'immunothérapie Projections Financières
BRIEF published on 04/03/2024 at 13:05, 7 months 17 days ago Kintara Therapeutics and TuHURA Biosciences Announce Merger Agreement to Advance Oncology Pipeline Merger Agreement Oncology Therapeutics Phase 3 Trials Immunotherapy Resistance Financial Projections
PRESS RELEASE published on 04/03/2024 at 13:00, 7 months 17 days ago Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement TuHURA and Kintara announce merger for advancing late-stage oncology pipeline with focus on personalized cancer vaccines and bi-functional ADCs. $31 million funding secured for operations till late 2025. Joint conference call scheduled for April 3, 2024 Merger Personalized Cancer Vaccines TuHURA Kintara Oncology Pipeline
PRESS RELEASE published on 02/07/2024 at 16:00, 9 months 13 days ago TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development TuHURA Biosciences, Inc. appoints Dr. Dennis Yamashita as Chief Scientific Officer and Head of Discovery Research and Early Development to advance novel personalized cancer vaccines and bi-functional antibody drug conjugates. Dr. Yamashita brings over 30 years of experience in R&D drug discovery and development TuHURA Biosciences Dr. Dennis Yamashita Personalized Cancer Vaccines Bi-functional Antibody Drug Conjugates Immuno-oncology
Published on 11/21/2024 at 10:03, 1 hour 37 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 40 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 40 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 5 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 11 hours 15 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 11:01, 38 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 39 minutes ago First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 43 minutes ago ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 9 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 1 hour 35 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 06:58, 4 hours 42 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 42 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 42 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 32 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 19 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting